{"doc_id": "si-2024-0162-reg-1", "parent_doc_id": "si-2024-0162", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 162 of 2024", "title": "(Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines", "year": 2024, "heading": "1. (1) These Regulations may be cited as the Medicinal Products", "text_raw": "1. (1) These Regulations may be cited as the Medicinal Products \n\n(Prescription and Control of Supply) (Amendment) (No. 3) Regulations 2024. \n\n(2) The collective citation “the Medicinal Products (Prescription and \n\nControl of Supply) Regulations 2003 to 2024” includes these Regulations.", "text_norm": "1 (1) regulation may cited medicinal product (prescription control supply) (amendment) (no 3) regulation 2024 (2) collective citation medicinal product (prescription control supply) regulation 2003 2024 includes regulation", "start_char": 618, "end_char": 908, "source_path": "downloads\\2024\\2024_0162.pdf", "extraction_method": "pdfminer", "checksum": "sha256:ccd9b873900b9d3390931d4af199bd327edffcbc4eee1ab83a28d0db0bfb60a1", "cross_refs": []}
{"doc_id": "si-2024-0162-reg-2", "parent_doc_id": "si-2024-0162", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 162 of 2024", "title": "(Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines", "year": 2024, "heading": "In these Regulations—", "text_raw": "2. \n\nIn these Regulations— \n\n“Principal Regulations” means the Medicinal Products (Prescription and \nControl of Supply) Regulations 2003 (S.I. No. 540 of 2003); \n\n“Regulations of 2023” means the Medicinal Products (Prescription and Control \nof Supply) (No. 7) Regulations 2023 (S.I. No. 584 of 2023).", "text_norm": "2 regulations-- principal regulation mean medicinal product (prescription control supply) regulation 2003 (s.i no 540 2003) regulation 2023 mean medicinal product (prescription control supply) (no 7) regulation 2023 (s.i no 584 2023)", "start_char": 908, "end_char": 1211, "source_path": "downloads\\2024\\2024_0162.pdf", "extraction_method": "pdfminer", "checksum": "sha256:ccd9b873900b9d3390931d4af199bd327edffcbc4eee1ab83a28d0db0bfb60a1", "cross_refs": []}
{"doc_id": "si-2024-0162-reg-3", "parent_doc_id": "si-2024-0162", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 162 of 2024", "title": "(Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines", "year": 2024, "heading": "3. The Eighth Schedule (as amended by Regulation 3 of the Regulations", "text_raw": "3. The Eighth Schedule (as amended by Regulation 3 of the Regulations \n\nof 2023) to the Principal Regulations is amended— \n\n(a) \n\nin column 5 of the entry for “Comirnaty 3 micrograms/dose \nconcentrate for dispersion for injection COVID-19 mRNA \nVaccine (nucleoside modified) Paediatric pack”, by deleting \n“Administered as a course of 3 doses of (0.2ml) each”, \n\n(b) by substituting for column 5 of the entry for “Comirnaty \nOriginal/Omicron BA.4-5 (5/5 micrograms)/dose concentrate \nfor dispersion for \ninjection COVID-19 mRNA Vaccine \n(nucleoside modified)” the following: \n“In accordance with the summary of product characteristics of \nthe product administered and/or relevant guidelines issued by \nthe National Immunisation Advisory Committee and accepted \nby the Minister for Health.”, \nin column 2 of the entry for “Naloxone injection”, by deleting \n“1mg/ml”, \nin column 2 of the entry for “Naloxone Nasal Spray”, by \ndeleting “1.8 mg”, and \n\n(d) \n\n(c) \n\n(e) by inserting the following entry: \n\n“ \n\nMedicinal Product \n\nForm and \npresentation \nof product \nadministered \n\nRoute of \nadministration \n\nIndication for \nwhich the \nmedicinal \nproduct may \nbe \n\nDosage and \nconditions of \nadministration \n\nPlace of \nadministration \n\nNotice of the making of this Statutory Instrument was published in \n\"Iris Oifigiúil\" of 23rd April, 2024. \n\n \n \n \n \n \n \n\fColumn 1 \n\nColumn 2 \n\nColumn 3 \n\nColumn 4 \n\nColumn 5 \n\nColumn 6 \n\nadministered \n\n[162] 3 \n\nConcentrate \nfor dispersion \nfor injection. \n\nIntramuscular \ninjection \n\nComirnaty Omicron \nXBB.1.5 3 \nmicrograms/dose \nconcentrate for \ndispersion for \ninjection COVID19 mRNA Vaccine \n\nActive \nimmunisation \nto prevent \nCOVID-19 \ncaused by \nSARS-CoV2 in infants \nand children \naged 6 \nmonths to 4 \nyears. \n\nIn accordance with \nthe summary of \nproduct \ncharacteristics of \nthe product \nadministered \nand/or relevant \nguidelines issued \nby the National \nImmunisation \nAdvisory \nCommittee and \naccepted by the \nMinister for \nHealth. \n\nAny suitable and \nappropriate \nplace, having \nregard to public \nconvenience and \nthe need to \nprotect the \nhealth and safety \nof the public and \nsafely \nadminister the \nproduct. \n\n”.", "text_norm": "3 eighth schedule (as amended regulation 3 regulation 2023) principal regulation amended-- (a) column 5 entry comirnaty 3 microgram dose concentrate dispersion injection covid-19 mrna vaccine (nucleoside modified) paediatric pack deleting administered course 3 dos (0.2ml) (b) substituting column 5 entry comirnaty original omicron ba.4-5 (5 5 micrograms) dose concentrate dispersion injection covid-19 mrna vaccine (nucleoside modified) following accordance summary product characteristic product administered relevant guideline issued national immunisation advisory committee accepted minister health column 2 entry naloxone injection deleting 1mg ml column 2 entry naloxone nasal spray deleting 1.8 mg (d) (c) (e) inserting following entry medicinal product form presentation product administered route administration indication medicinal product may dosage condition administration place administration notice making statutory instrument published iris oifigiuil 23rd april 2024 column 1 column 2 column 3 column 4 column 5 column 6 administered 162 3 concentrate dispersion injection intramuscular injection comirnaty omicron xbb.1.5 3 microgram dose concentrate dispersion injection covid19 mrna vaccine active immunisation prevent covid-19 caused sars-cov2 infant child aged 6 month 4 year accordance summary product characteristic product administered relevant guideline issued national immunisation advisory committee accepted minister health suitable appropriate place regard public convenience need protect health safety public safely administer product", "start_char": 1211, "end_char": 3370, "source_path": "downloads\\2024\\2024_0162.pdf", "extraction_method": "pdfminer", "checksum": "sha256:ccd9b873900b9d3390931d4af199bd327edffcbc4eee1ab83a28d0db0bfb60a1", "cross_refs": []}
{"doc_id": "si-2024-0162-reg-4", "parent_doc_id": "si-2024-0162", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 162 of 2024", "title": "(Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines", "year": 2024, "heading": "4. The Tenth Schedule (as amended by Regulation 3 of the Medicinal", "text_raw": "4. The Tenth Schedule (as amended by Regulation 3 of the Medicinal \nProducts (Prescription and Control of Supply) (Amendment) (No. 3) \nRegulations 2023 (S.I. No. 238 of 2023)) to the Principal Regulations is \namended— \n\n(a) \n\n(b) \n\nin column 2 of the entry for “Naloxone injection”, by deleting \n“1mg/ml”, and \nin column 2 of the entry for “Naloxone Nasal Spray”, by \ndeleting “1.8 mg”", "text_norm": "4 tenth schedule (as amended regulation 3 medicinal product (prescription control supply) (amendment) (no 3) regulation 2023 (s.i no 238 2023)) principal regulation amended-- (a) (b) column 2 entry naloxone injection deleting 1mg ml column 2 entry naloxone nasal spray deleting 1.8 mg", "start_char": 3370, "end_char": 3758, "source_path": "downloads\\2024\\2024_0162.pdf", "extraction_method": "pdfminer", "checksum": "sha256:ccd9b873900b9d3390931d4af199bd327edffcbc4eee1ab83a28d0db0bfb60a1", "cross_refs": []}
{"doc_id": "si-2024-0162-reg-5", "parent_doc_id": "si-2024-0162", "section_id": "reg-5", "section_label": "Regulation 5.", "si_number": "S.I. No. 162 of 2024", "title": "(Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines", "year": 2024, "heading": "5. The Twelfth Schedule (as amended by Regulation 4 of the Regulations", "text_raw": "5. The Twelfth Schedule (as amended by Regulation 4 of the Regulations \n\nof 2023) to the Principal Regulations is amended— \n\n(a) \n\nin column 5 of the entry for “Comirnaty 3 micrograms/dose \nconcentrate for dispersion for injection COVID-19 mRNA \nVaccine (nucleoside modified) Paediatric pack”, by deleting \n“Administered as a course of 3 doses of (0.2ml) each”, \n\n(b) by substituting for column 5 of the entry for “Comirnaty \nOriginal/Omicron BA.4-5 (5/5 micrograms)/dose concentrate \nfor dispersion for \ninjection COVID-19 mRNA Vaccine \n(nucleoside modified)” the following: \n“In accordance with the summary of product characteristics of \nthe product administered and/or relevant guidelines issued by \nthe National Immunisation Advisory Committee and accepted \nby the Minister for Health.”, and \n(c) by inserting the following entry: \n\n“ \n\nMedicinal product \n\nForm and \npresentation \nof product \nadministered \n\nRoute of \nadministration \n\nIndication for which \nthe medicinal product \nmay be administered \n\nDosage and conditions \nof administration \n\nColumn 1 \n\nColumn 2 \n\nColumn 3 \n\nColumn 4 \n\nColumn 5 \n\n \n \n \n \n \n\f4 [162] \n\nMedicinal product \n\nComirnaty Omicron \nXBB.1.5 3 \nmicrograms/dose \nconcentrate for \ndispersion for \ninjection COVID-19 \nmRNA Vaccine \n\n”. \n\nForm and \npresentation \nof product \nadministered \n\nRoute of \nadministration \n\nIndication for which \nthe medicinal product \nmay be administered \n\nDosage and conditions \nof administration \n\nConcentrate \nfor dispersion \nfor injection. \n\nIntramuscular \ninjection \n\nActive immunisation \nto prevent COVID-19 \ncaused by SARS-CoV2 in infants and \nchildren aged 6 \nmonths to 4 years. \n\nIn accordance with the \nsummary of product \ncharacteristics of the \nproduct administered \nand/or relevant \nguidelines issued by the \nNational Immunisation \nAdvisory Committee and \naccepted by the Minister \nfor Health. \n\nGIVEN under my Official Seal, \n\n22 April, 2024. \n\nSTEPHEN DONNELLY, \nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n \n \n \n\f[162] 5", "text_norm": "5 twelfth schedule (as amended regulation 4 regulation 2023) principal regulation amended-- (a) column 5 entry comirnaty 3 microgram dose concentrate dispersion injection covid-19 mrna vaccine (nucleoside modified) paediatric pack deleting administered course 3 dos (0.2ml) (b) substituting column 5 entry comirnaty original omicron ba.4-5 (5 5 micrograms) dose concentrate dispersion injection covid-19 mrna vaccine (nucleoside modified) following accordance summary product characteristic product administered relevant guideline issued national immunisation advisory committee accepted minister health (c) inserting following entry medicinal product form presentation product administered route administration indication medicinal product may administered dosage condition administration column 1 column 2 column 3 column 4 column 5 4 162 medicinal product comirnaty omicron xbb.1.5 3 microgram dose concentrate dispersion injection covid-19 mrna vaccine  form presentation product administered route administration indication medicinal product may administered dosage condition administration concentrate dispersion injection intramuscular injection active immunisation prevent covid-19 caused sars-cov2 infant child aged 6 month 4 year accordance summary product characteristic product administered relevant guideline issued national immunisation advisory committee accepted minister health given official seal 22 april 2024 stephen donnelly minister health 162 5", "start_char": 3758, "end_char": 5747, "source_path": "downloads\\2024\\2024_0162.pdf", "extraction_method": "pdfminer", "checksum": "sha256:ccd9b873900b9d3390931d4af199bd327edffcbc4eee1ab83a28d0db0bfb60a1", "cross_refs": []}
{"doc_id": "si-2024-0162-explanatory-note", "parent_doc_id": "si-2024-0162", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 162 of 2024", "title": "(Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines", "year": 2024, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation.) \n\nThese Regulations amend the Medicinal Products (Prescription and Control of \nSupply) Regulations 2003. \n\nThe purpose of these Regulations is to make amendments and additions to the \nlists of medicinal products in the Eighth, Tenth and Twelfth Schedules. \n\nThese Regulations may be cited as the Medicinal Products (Prescription and \nControl of Supply) (Amendment) (No. 3) Regulations 2024. \n\n \n \n \n \n \n \n \n \n\f6 [162] \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€ 3.50 \n\n(DH-530) 30. 4/24. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) regulation amend medicinal product (prescription control supply) regulation 2003 purpose regulation make amendment addition list medicinal product eighth tenth twelfth schedule regulation may cited medicinal product (prescription control supply) (amendment) (no 3) regulation 2024 6 162 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur 3.50 (dh-530) 30 4 24 propylon", "start_char": 5747, "end_char": 6763, "source_path": "downloads\\2024\\2024_0162.pdf", "extraction_method": "pdfminer", "checksum": "sha256:ccd9b873900b9d3390931d4af199bd327edffcbc4eee1ab83a28d0db0bfb60a1", "cross_refs": []}
